CDK9 and hematopoietic and lymphoid cell neoplasm: However, when we combined BTYNB with AZD4573, a highly selective CDK9 inhibitor that has recently been shown to induce apoptosis in hematologic cancer (32), we observed a synergistic effect between both inhibitors, significantly decreasing cell proliferation in each neuroblastoma cell line tested.